Medtronic PLC (NYSE:MDT) Position Decreased by Braun Bostich & Associates Inc.
Braun Bostich & Associates Inc. reduced its holdings in Medtronic PLC (NYSE:MDT) by 6.7% during the first quarter, Holdings Channel reports. The firm owned 5,203 shares of the medical technology company’s stock after selling 375 shares during the period. Braun Bostich & Associates Inc.’s holdings in Medtronic were worth $438,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Medtronic during the fourth quarter worth $1,648,853,000. Investec Asset Management LTD purchased a new position in Medtronic in the 4th quarter worth about $494,986,000. Amundi Pioneer Asset Management Inc. raised its holdings in Medtronic by 23.2% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 8,968,638 shares of the medical technology company’s stock worth $1,017,493,000 after buying an additional 1,690,287 shares during the period. M&G Investment Management Ltd. acquired a new stake in Medtronic during the 4th quarter worth about $167,466,000. Finally, Geode Capital Management LLC lifted its stake in Medtronic by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 19,687,292 shares of the medical technology company’s stock valued at $2,229,034,000 after buying an additional 1,225,925 shares in the last quarter. 81.74% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on MDT shares. Citigroup cut their price target on shares of Medtronic from $124.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Sanford C. Bernstein reissued a “hold” rating and set a $112.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Cfra upgraded Medtronic from a “buy” rating to a “strong-buy” rating and reduced their target price for the company from $127.00 to $121.00 in a report on Thursday. Credit Suisse Group lowered their price target on Medtronic from $126.00 to $121.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Finally, DZ Bank downgraded Medtronic from a “buy” rating to a “hold” rating and set a $92.00 price objective for the company. in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $115.03.
Medtronic (NYSE:MDT) last announced its quarterly earnings results on Thursday, May 21st. The medical technology company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.28 by ($0.70). The company had revenue of $6 billion during the quarter, compared to analyst estimates of $6.10 billion. Medtronic had a return on equity of 14.76% and a net margin of 17.11%. Medtronic’s quarterly revenue was down 26.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.54 EPS. On average, sell-side analysts predict that Medtronic PLC will post 4.68 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a dividend of $0.58 per share. This represents a $2.32 annualized dividend and a yield of 2.47%. The ex-dividend date is Thursday, June 25th. This is an increase from Medtronic’s previous quarterly dividend of $0.54. Medtronic’s dividend payout ratio (DPR) is 41.38%.
Medtronic Company Profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.